Preclinical activity of anti-CCR7 immunotherapy in patients with high-risk chronic lymphocytic leukemia

Refractory chronic lymphocytic leukemia – new therapeutic strategies

(2015)   Oncotarget

Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia

(2014) Richard R. Furman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Anti-CCR7 therapy exerts a potent anti-tumor activity in a xenograft model of human mantle cell lymphoma

(2013) Beatriz Somovilla-Crespo et al.   Journal of Hematology & Oncology

Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial

(2013) Susan O'Brien et al.   LANCET ONCOLOGY

Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia

(2013) John C. Byrd et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ofatumumab is active in patients with fludarabine-refractory CLL irrespective of prior rituximab: results from the phase 2 international study

(2011) W. G. Wierda et al.   BLOOD

Advances in the assessment and control of the effector functions of therapeutic antibodies

(2011) Xu-Rong Jiang et al.   NATURE REVIEWS DRUG DISCOVERY

Understanding and Managing Ultra High-Risk Chronic Lymphocytic Leukemia

(2011) S. Stilgenbauer et al.   Hematology-American Society of Hematology Education Program

The Treatment of Relapsed Refractory Chronic Lymphocytic Leukemia

(2011) J. R. Brown   Hematology-American Society of Hematology Education Program

Clinical outcome of pretreated B-cell chronic lymphocytic leukemia following alemtuzumab therapy: a retrospective study on various cytogenetic risk categories

(2010) M. Fiegl et al.   ANNALS OF ONCOLOGY

Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity

(2010) E. Mossner et al.   BLOOD

Analysis of migratory and prosurvival pathways induced by the homeostatic chemokines CCL19 and CCL21 in B-cell chronic lymphocytic leukemia

(2010) Carlos Cuesta-Mateos et al.   EXPERIMENTAL HEMATOLOGY

Ofatumumab As Single-Agent CD20 Immunotherapy in Fludarabine-Refractory Chronic Lymphocytic Leukemia

(2010) William G. Wierda et al.   JOURNAL OF CLINICAL ONCOLOGY

TP53Mutation and Survival in Chronic Lymphocytic Leukemia

(2010) Thorsten Zenz et al.   JOURNAL OF CLINICAL ONCOLOGY

Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial

(2010) M Hallek et al.   LANCET

Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial

(2009) T. Zenz et al.   BLOOD

Expression of chemokine receptors CXCR4, CXCR5 and CCR7 on B and T lymphocytes from patients with primary antibody deficiency

(2009) D. Payne et al.   CLINICAL AND EXPERIMENTAL IMMUNOLOGY

Subcutaneous Alemtuzumab in Fludarabine-Refractory Chronic Lymphocytic Leukemia: Clinical Results and Prognostic Marker Analyses From the CLL2H Study of the German Chronic Lymphocytic Leukemia Study Group

(2009) Stephan Stilgenbauer et al.   JOURNAL OF CLINICAL ONCOLOGY

Phenotypic and functional characterization of switch memory B cells from patients with oligoarticular juvenile idiopathic arthritis

(2009) Anna Corcione et al.   ARTHRITIS RESEARCH & THERAPY

Lenalidomide down-regulates the CD20 antigen and antagonizes direct and antibody-dependent cellular cytotoxicity of rituximab on primary chronic lymphocytic leukemia cells

(2008) R. Lapalombella et al.   BLOOD

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines

(2008) M. Hallek et al.   BLOOD

CXCR4 antagonists: targeting the microenvironment in leukemia and other cancers

(2008) J A Burger et al.   LEUKEMIA